English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Growing evidence indicate that comorbidity has an unfavourable effect on life expectancy of patients with myelodysplastic syndromes (MDS), and significantly influences clinical decision making. In this report we we compared the ability to capture prognostic information on comorbidity in MDS by general comorbidity measures (ACE-27 scale) versus disease-specific comorbidity measures (MDS-CI) in 840 consecutive patients diagnosed at our institution between 1992 and 2007. For all comorbid conditions considered in the analysis, clinical definition and grading of severity by MDS-CI resulted more fit for capturing the prognostic information of these comorbid conditions in MDS patients compared to ACE-27.

Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool